[{"id":"743006a6-c939-4023-8010-4e3aee085ae3","acronym":"E7386-J081-102","url":"https://clinicaltrials.gov/study/NCT04008797","created_at":"2022-06-28T02:54:50.954Z","updated_at":"2025-02-25T15:18:13.404Z","phase":"Phase 1/2","brief_title":"A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor","source_id_and_acronym":"NCT04008797 - E7386-J081-102","lead_sponsor":"Eisai Inc.","biomarkers":" EGFR • KRAS • BRAF • MSI","pipe":" | ","alterations":" BRAF V600E • MSI-H/dMMR • BRAF V600 • KRAS wild-type • NRAS wild-type","tags":["EGFR • KRAS • BRAF • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • MSI-H/dMMR • BRAF V600 • KRAS wild-type • NRAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • Lenvima (lenvatinib) • doxorubicin hydrochloride • E7386"],"overall_status":"Recruiting","enrollment":" Enrollment 301","initiation":"Initiation: 07/11/2019","start_date":" 07/11/2019","primary_txt":" Primary completion: 11/30/2026","primary_completion_date":" 11/30/2026","study_txt":" Completion: 11/30/2026","study_completion_date":" 11/30/2026","last_update_posted":"2025-02-11"},{"id":"6983d949-ecb2-40d9-9de6-9dd357d15cfa","acronym":"KEYNOTE-C83","url":"https://clinicaltrials.gov/study/NCT05091346","created_at":"2021-10-25T11:52:57.520Z","updated_at":"2025-02-25T16:16:50.707Z","phase":"Phase 1/2","brief_title":"A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid Tumors","source_id_and_acronym":"NCT05091346 - KEYNOTE-C83","lead_sponsor":"Eisai Inc.","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Lenvima (lenvatinib) • E7386"],"overall_status":"Completed","enrollment":" Enrollment 89","initiation":"Initiation: 10/27/2021","start_date":" 10/27/2021","primary_txt":" Primary completion: 10/15/2024","primary_completion_date":" 10/15/2024","study_txt":" Completion: 10/15/2024","study_completion_date":" 10/15/2024","last_update_posted":"2024-10-24"},{"id":"a47ddf13-3816-49fc-80b2-c615e6b61c98","acronym":"","url":"https://clinicaltrials.gov/study/NCT03264664","created_at":"2023-11-04T04:12:31.080Z","updated_at":"2024-07-02T16:34:27.421Z","phase":"Phase 1","brief_title":"Study of E7386 in Participants With Selected Advanced Neoplasms","source_id_and_acronym":"NCT03264664","lead_sponsor":"Eisai Inc.","biomarkers":" CTNNB1","pipe":" | ","alterations":" CTNNB1 mutation","tags":["CTNNB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CTNNB1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e E7386"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 07/27/2017","start_date":" 07/27/2017","primary_txt":" Primary completion: 03/31/2026","primary_completion_date":" 03/31/2026","study_txt":" Completion: 03/31/2026","study_completion_date":" 03/31/2026","last_update_posted":"2024-06-11"},{"id":"627558e9-c3d7-4f51-90e5-5a44fbbddb52","acronym":"","url":"https://clinicaltrials.gov/study/NCT01351103","created_at":"2021-01-18T05:31:16.537Z","updated_at":"2024-07-02T16:34:59.934Z","phase":"Phase 1","brief_title":"A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands","source_id_and_acronym":"NCT01351103","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" BRAF • RNF43","pipe":" | ","alterations":" BRAF mutation • RNF43 mutation","tags":["BRAF • RNF43"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • RNF43 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e spartalizumab (PDR001) • WNT974"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 185","initiation":"Initiation: 12/01/2011","start_date":" 12/01/2011","primary_txt":" Primary completion: 06/14/2021","primary_completion_date":" 06/14/2021","study_txt":" Completion: 06/18/2024","study_completion_date":" 06/18/2024","last_update_posted":"2024-05-30"},{"id":"00386017-fdba-4646-91db-e52d18a56ce7","acronym":"PEPN2011","url":"https://clinicaltrials.gov/study/NCT04851119","created_at":"2021-04-20T14:55:40.726Z","updated_at":"2024-07-02T16:35:08.278Z","phase":"Phase 1/2","brief_title":"Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors","source_id_and_acronym":"NCT04851119 - PEPN2011","lead_sponsor":"Children's Oncology Group","biomarkers":" RNF43 • CTNNB1 • TCF7L2","pipe":" | ","alterations":" APC mutation • CTNNB1 mutation • RNF43 mutation • CTNNB1 S45P","tags":["RNF43 • CTNNB1 • TCF7L2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e APC mutation • CTNNB1 mutation • RNF43 mutation • CTNNB1 S45P"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tegavivint (BC2059)"],"overall_status":"Recruiting","enrollment":" Enrollment 147","initiation":"Initiation: 11/08/2021","start_date":" 11/08/2021","primary_txt":" Primary completion: 06/30/2028","primary_completion_date":" 06/30/2028","study_txt":" Completion: 06/30/2028","study_completion_date":" 06/30/2028","last_update_posted":"2024-04-22"},{"id":"d1c8d534-b991-4bdd-aee5-250c8074853d","acronym":"","url":"https://clinicaltrials.gov/study/NCT03833700","created_at":"2023-07-12T22:09:04.322Z","updated_at":"2024-07-02T16:35:16.167Z","phase":"Phase 1","brief_title":"A Study of E7386 in Participants With Advanced Solid Tumor Including Colorectal Cancer (CRC)","source_id_and_acronym":"NCT03833700","lead_sponsor":"Eisai Co., Ltd.","biomarkers":" RNF43 • APC • AXIN1 • ZNRF3","pipe":" | ","alterations":" APC mutation • CTNNB1 mutation • RNF43 mutation","tags":["RNF43 • APC • AXIN1 • ZNRF3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e APC mutation • CTNNB1 mutation • RNF43 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e E7386"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 70","initiation":"Initiation: 03/05/2019","start_date":" 03/05/2019","primary_txt":" Primary completion: 03/31/2025","primary_completion_date":" 03/31/2025","study_txt":" Completion: 03/31/2025","study_completion_date":" 03/31/2025","last_update_posted":"2024-03-06"},{"id":"4c415dce-6421-46bd-97fd-5cc700ebf780","acronym":"","url":"https://clinicaltrials.gov/study/NCT05797805","created_at":"2023-04-04T16:04:03.714Z","updated_at":"2024-07-02T16:35:18.401Z","phase":"Phase 1/2","brief_title":"A Study of Tegavivint (BC2059) in Patients With Advanced Hepatocellular Carcinoma","source_id_and_acronym":"NCT05797805","lead_sponsor":"Iterion Therapeutics","biomarkers":" AXIN1","pipe":" | ","alterations":" CTNNB1 mutation","tags":["AXIN1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CTNNB1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • tegavivint (BC2059)"],"overall_status":"Recruiting","enrollment":" Enrollment 108","initiation":"Initiation: 09/13/2023","start_date":" 09/13/2023","primary_txt":" Primary completion: 05/01/2026","primary_completion_date":" 05/01/2026","study_txt":" Completion: 06/01/2026","study_completion_date":" 06/01/2026","last_update_posted":"2024-02-21"},{"id":"300dc214-2f53-46f4-88db-099cbeecb27f","acronym":"","url":"https://clinicaltrials.gov/study/NCT05755087","created_at":"2023-03-06T15:01:37.165Z","updated_at":"2024-07-02T16:35:24.905Z","phase":"Phase 1","brief_title":"Tegavivint for Treating Patients With Relapsed or Refractory Large B-Cell Lymphoma","source_id_and_acronym":"NCT05755087","lead_sponsor":"Lapo Alinari","biomarkers":" MYC • BCL2 • BCL6","pipe":" | ","alterations":" BCL2 expression • MYC expression • MYC translocation • MYC translocation + BCL2 translocation • BCL2 translocation","tags":["MYC • BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL2 expression • MYC expression • MYC translocation • MYC translocation + BCL2 translocation • BCL2 translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tegavivint (BC2059)"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 03/06/2023","start_date":" 03/06/2023","primary_txt":" Primary completion: 03/05/2027","primary_completion_date":" 03/05/2027","study_txt":" Completion: 03/05/2027","study_completion_date":" 03/05/2027","last_update_posted":"2023-12-29"},{"id":"a57663a3-200f-4a64-8df5-537b7c4835d2","acronym":"","url":"https://clinicaltrials.gov/study/NCT04780568","created_at":"2023-12-11T17:16:35.473Z","updated_at":"2024-07-02T16:35:26.635Z","phase":"Phase 1","brief_title":"Osimertinib and Tegavivint as First-Line Therapy for the Treatment of Metastatic EGFR-Mutant Non-small Cell Lung Cancer","source_id_and_acronym":"NCT04780568","lead_sponsor":"Ohio State University Comprehensive Cancer Center","biomarkers":" EGFR • NOTCH3","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR L861Q • EGFR G719X • EGFR S768I","tags":["EGFR • NOTCH3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR L861Q • EGFR G719X • EGFR S768I"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib) • tegavivint (BC2059)"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 01/18/2022","start_date":" 01/18/2022","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2023-12-11"},{"id":"8e871962-d882-425c-bf52-00aaa004787b","acronym":"Keynote 596","url":"https://clinicaltrials.gov/study/NCT02675946","created_at":"2022-01-26T19:54:54.091Z","updated_at":"2025-02-25T16:04:17.687Z","phase":"Phase 1b","brief_title":"CGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab or Encorafenib + Cetuximab in Subjects With Advanced GI Tumors (Keynote 596)","source_id_and_acronym":"NCT02675946 - Keynote 596","lead_sponsor":"Curegenix Inc.","biomarkers":" BRAF • RNF43 • CTNNB1 • AXIN1 • RSPO2 • RSPO3","pipe":" | ","alterations":" BRAF V600E • BRAF V600","tags":["BRAF • RNF43 • CTNNB1 • AXIN1 • RSPO2 • RSPO3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Erbitux (cetuximab) • Braftovi (encorafenib) • CGX1321"],"overall_status":"Recruiting","enrollment":" Enrollment 72","initiation":"Initiation: 02/01/2016","start_date":" 02/01/2016","primary_txt":" Primary completion: 03/01/2023","primary_completion_date":" 03/01/2023","study_txt":" Completion: 03/01/2023","study_completion_date":" 03/01/2023","last_update_posted":"2022-01-26"},{"id":"b38f7192-0406-4c42-9815-ea388526bccb","acronym":"","url":"https://clinicaltrials.gov/study/NCT01973309","created_at":"2021-01-17T17:42:44.579Z","updated_at":"2024-07-02T16:36:41.269Z","phase":"Phase 1b","brief_title":"A Study of Vantictumab (OMP-18R5) in Combination With Paclitaxel in Locally Recurrent or Metastatic Breast Cancer","source_id_and_acronym":"NCT01973309","lead_sponsor":"OncoMed Pharmaceuticals, Inc.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 overexpression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • vantictumab (OMP-18R5)"],"overall_status":"Completed","enrollment":" Enrollment 37","initiation":"Initiation: 09/01/2013","start_date":" 09/01/2013","primary_txt":" Primary completion: 06/01/2017","primary_completion_date":" 06/01/2017","study_txt":" Completion: 12/01/2017","study_completion_date":" 12/01/2017","last_update_posted":"2020-09-09"},{"id":"0f58a0ca-0ebd-407c-a07e-347f60642792","acronym":"","url":"https://clinicaltrials.gov/study/NCT02278133","created_at":"2021-01-18T10:43:25.747Z","updated_at":"2024-07-02T16:37:17.241Z","phase":"Phase 1/2","brief_title":"Study of WNT974 in Combination With LGX818 and Cetuximab in Patients With BRAF-mutant Metastatic Colorectal Cancer (mCRC) and Wnt Pathway Mutations","source_id_and_acronym":"NCT02278133","lead_sponsor":"Array BioPharma","biomarkers":" KRAS • RNF43","pipe":" | ","alterations":" KRAS mutation • BRAF V600 • KRAS wild-type • RAS wild-type • RNF43 mutation","tags":["KRAS • RNF43"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • BRAF V600 • KRAS wild-type • RAS wild-type • RNF43 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • Braftovi (encorafenib) • WNT974"],"overall_status":"Completed","enrollment":" Enrollment 20","initiation":"Initiation: 12/01/2014","start_date":" 12/01/2014","primary_txt":" Primary completion: 05/31/2016","primary_completion_date":" 05/31/2016","study_txt":" Completion: 06/23/2017","study_completion_date":" 06/23/2017","last_update_posted":"2017-10-09"},{"id":"2cc142f0-936b-4d7c-a88d-8efcc58b34ae","acronym":"","url":"https://clinicaltrials.gov/study/NCT01606579","created_at":"2021-01-18T06:52:25.296Z","updated_at":"2024-07-02T16:37:18.780Z","phase":"Phase 1/2","brief_title":"Safety and Efficacy Study of PRI-724 in Subjects With Advanced Myeloid Malignancies","source_id_and_acronym":"NCT01606579","lead_sponsor":"Prism Pharma Co., Ltd.","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • foscenvivint (PRI724)"],"overall_status":"Completed","enrollment":" Enrollment 49","initiation":"Initiation: 07/01/2012","start_date":" 07/01/2012","primary_txt":" Primary completion: 12/30/2016","primary_completion_date":" 12/30/2016","study_txt":" Completion: 12/30/2016","study_completion_date":" 12/30/2016","last_update_posted":"2017-08-17"},{"id":"df9ef5ca-d318-4e93-9501-779e49ce9ce1","acronym":"","url":"https://clinicaltrials.gov/study/NCT01764477","created_at":"2021-01-18T07:45:28.718Z","updated_at":"2024-07-02T16:37:18.793Z","phase":"Phase 1","brief_title":"Safety and Efficacy Study of PRI-724 Plus Gemcitabine in Subjects With Advanced or Metastatic Pancreatic Adenocarcinoma","source_id_and_acronym":"NCT01764477","lead_sponsor":"Prism Pharma Co., Ltd.","biomarkers":" BIRC5 • MMP7","pipe":" | ","alterations":" BIRC5 expression","tags":["BIRC5 • MMP7"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BIRC5 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • 5-fluorouracil • oxaliplatin • irinotecan • leucovorin calcium • foscenvivint (PRI724)"],"overall_status":"Completed","enrollment":" Enrollment 20","initiation":"Initiation: 04/01/2013","start_date":" 04/01/2013","primary_txt":" Primary completion: 10/01/2015","primary_completion_date":" 10/01/2015","study_txt":" Completion: 10/01/2015","study_completion_date":" 10/01/2015","last_update_posted":"2017-08-17"},{"id":"5a7c5489-b239-47d8-a356-42d94714ee1a","acronym":"PRIMIER","url":"https://clinicaltrials.gov/study/NCT02413853","created_at":"2021-01-18T11:31:51.660Z","updated_at":"2024-07-02T16:37:23.393Z","phase":"Phase 2","brief_title":"Combination Chemotherapy and Bevacizumab With or Without PRI-724 in Treating Patients With Newly Diagnosed Metastatic Colorectal Cancer","source_id_and_acronym":"NCT02413853 - PRIMIER","lead_sponsor":"University of Southern California","biomarkers":" BRAF • BIRC5","pipe":" | ","alterations":" BIRC5 expression","tags":["BRAF • BIRC5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BIRC5 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • 5-fluorouracil • oxaliplatin • leucovorin calcium • foscenvivint (PRI724)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 11/01/2015","start_date":" 11/01/2015","primary_txt":" Primary completion: 11/01/2017","primary_completion_date":" 11/01/2017","study_txt":" Completion: 11/01/2018","study_completion_date":" 11/01/2018","last_update_posted":"2017-04-17"}]